189 related articles for article (PubMed ID: 20836577)
1. Aztreonam lysine for inhalation solution: in cystic fibrosis.
Plosker GL
Drugs; 2010 Oct; 70(14):1843-55. PubMed ID: 20836577
[TBL] [Abstract][Full Text] [Related]
2. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
3. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
[TBL] [Abstract][Full Text] [Related]
4. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
Pesaturo KA; Horton ER; Belliveau P
Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
[TBL] [Abstract][Full Text] [Related]
5. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
[TBL] [Abstract][Full Text] [Related]
6. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
[TBL] [Abstract][Full Text] [Related]
8. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
[TBL] [Abstract][Full Text] [Related]
10. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB
J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
12. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
[TBL] [Abstract][Full Text] [Related]
13. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG
Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045
[TBL] [Abstract][Full Text] [Related]
14. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D
J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119
[TBL] [Abstract][Full Text] [Related]
15. Inhaled aztreonam.
O'Sullivan BP; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2010 May; 9(5):357-8. PubMed ID: 20431562
[TBL] [Abstract][Full Text] [Related]
16. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
17. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
[TBL] [Abstract][Full Text] [Related]
18. ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.
Gilchrist FJ; Bui S; Gartner S; McColley SA; Tiddens H; Ruiz G; Stehling F; Alani M; Gurtovaya O; Bresnik M; Watkins TR; Frankovic B; Skov M;
J Cyst Fibros; 2024 Jan; 23(1):80-86. PubMed ID: 37455237
[TBL] [Abstract][Full Text] [Related]
19. Aztreonam lysine for inhalation: new formulation of an old antibiotic.
Zeitler K; Salvas B; Stevens V; Brown J
Am J Health Syst Pharm; 2012 Jan; 69(2):107-15. PubMed ID: 22215356
[TBL] [Abstract][Full Text] [Related]
20. Inhaled aztreonam lysine: an evidence-based review.
Hutchinson D; Barclay M; Prescott WA; Brown J
Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
